Andrew Weil - Nov 2, 2021 Form 4 Insider Report for TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)

Role
Chief Accounting Officer
Signature
/s/ Dov Bergwerk as attorney in fact for Andrew Weil
Stock symbol
TEVA
Transactions as of
Nov 2, 2021
Transactions value $
$0
Form type
4
Date filed
11/4/2021, 07:27 AM

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TEVA Restricted Share Units Award $0 +29.7K $0.00 29.7K Nov 2, 2021 Ordinary Shares 29.7K Direct F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
F2 Restricted share units were granted on November 2, 2021, with 7,418 vesting on each of November 2, 2022, March 5, 2023 and March 5, 2024 and 7,419 vesting on March 5, 2025.
F3 The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.